| 5.95 -0.04 (-0.67%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.22 | 1-year : | 7.88 |
| Resists | First : | 6.18 | Second : | 6.75 |
| Pivot price | 6.07  |
|||
| Supports | First : | 5.28 | Second : | 4.39 |
| MAs | MA(5) : | 6.27 |
MA(20) : | 5.96 |
| MA(100) : | 5.86 |
MA(250) : | 4.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.8 |
D(3) : | 71.6 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 7.3 | Low : | 2.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TSHA ] has closed above bottom band by 41.9%. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.01 - 6.06 | 6.06 - 6.09 |
| Low: | 5.62 - 5.67 | 5.67 - 5.7 |
| Close: | 5.88 - 5.96 | 5.96 - 6.02 |
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Fri, 14 Aug 2026
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan
Thu, 13 Aug 2026
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - Stock Titan
Thu, 13 Aug 2026
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - finance.yahoo.com
Wed, 12 Aug 2026
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat
Wed, 12 Aug 2026
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView
Wed, 12 Aug 2026
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlig - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 287 (M) |
| Held by Insiders | 2.0597e+008 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 38,730 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3141e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 774.3 % |
| Return on Equity (ttm) | -37.8 % |
| Qtrly Rev. Growth | 7.47e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -81.75 |
| EBITDA (p.s.) | 6.27731e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 9.56 |
| Dividend | 0 |
| Forward Dividend | 4.529e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|